Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Inborn Errors of Metabolism

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...

Drug Toxicity: Allergic Reactions

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Piperine as Potential Anti-Inflammatory Agent: In-Silico Studies Along With In-Vitro Anti-Cathepsin B Activity, and Serum Protein Protection Validation.

Chemistry & biodiversity·2025

Same author

The Thermal and Mechanical Properties of Medium Chain-Length Polyhydroxyalkanoates Produced by <i>Pseudomonas putida</i> LS46 on Various Substrates.

Frontiers in bioengineering and biotechnology·2021

Same author

Microbial and Enzymatic Degradation of Synthetic Plastics.

Frontiers in microbiology·2020

Same author

Quorum sensing and the anaerobic regulator (ANR) control polyhydroxyalkanoate (PHA) production in Pseudomonas chlororaphis PA23.

FEMS microbiology letters·2019

Same author

Polyhydroxyalkanoate (PHA) Polymer Accumulation and <i>pha</i> Gene Expression in Phenazine (phz⁻) and Pyrrolnitrin (prn⁻) Defective Mutants of <i>Pseudomonas chlororaphis</i> PA23.

Polymers·2019

Same author

Colonization and degradation of polyhydroxyalkanoates by lipase-producing bacteria.

Canadian journal of microbiology·2019

Search research articles

Related Experiment Video

Updated: May 17, 2026

Sectioning Mammary Gland Whole Mounts for Lesion Identification

Sectioning Mammary Gland Whole Mounts for Lesion Identification

Published on: July 24, 2017

Gynecomastia caused by ethionamide.

Parveen K Sharma¹, Rekha Bansal

¹Department of Pharmacology, Dr. RP Govt. Medical College, Kangra at Tanda, Himachal Pradesh, India.

Indian Journal of Pharmacology

|November 1, 2012

Summary

A multidrug-resistant tuberculosis patient developed gynecomastia, a breast enlargement, during ethionamide treatment. Symptoms resolved after discontinuing the medication, suggesting ethionamide as the cause.

Area of Science:

Pharmacology
Endocrinology
Infectious Diseases

Background:

Multidrug-resistant tuberculosis (MDR-TB) requires complex, multi-drug treatment regimens.
Ethionamide is a second-line antitubercular drug used in MDR-TB treatment.
Adverse drug reactions can complicate treatment protocols.

Observation:

A 43-year-old male patient with MDR-TB developed a tender, 3x3 cm right breast lump after 4 months of antitubercular therapy.
Ultrasonography confirmed a hypoechoic mass behind the nipple, without infiltration of deeper structures.
Gynecomastia was suspected as a potential side effect of ethionamide.

Findings:

The patient was treated with anti-inflammatory drugs, which relieved pain but not the nodule.
Discontinuation of all antitubercular drugs by the patient led to the complete resolution of the breast nodule within a week.

Keywords:

Adverse drug reaction Ethionamide Gynecomastia

Related Experiment Videos

Last Updated: May 17, 2026

Sectioning Mammary Gland Whole Mounts for Lesion Identification

Sectioning Mammary Gland Whole Mounts for Lesion Identification

Published on: July 24, 2017

This temporal relationship strongly suggests ethionamide-induced gynecomastia.

Implications:

Ethionamide should be carefully monitored for potential endocrine side effects, particularly gynecomastia, in male patients.
Early recognition and management of drug-induced gynecomastia can improve patient comfort and adherence to TB treatment.
This case highlights the importance of considering drug-induced adverse events in differential diagnoses of breast masses in patients undergoing TB therapy.